LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global follicular lymphoma therapeutics market to grow at a CAGR of close to 8% during the forecast period, according to their latest market research report.
The increasing patient support programs are one of the major trends being witnessed in the global follicular lymphoma therapeutics market 2018-2022. Some of the top pharmaceutical companies are offering patient support programs to provide information about top-selling therapeutics such as Rituxan Hycela and Rituxan (rituximab), which increases the awareness about the treatment and cost range. Such support programs will assist the patients in selecting a treatment option, which, in turn, will drive market growth during the forecast period.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
According to Technavio analysts, one of the key factors contributing to the growth of the global follicular lymphoma therapeutics market is the increasing government initiatives.
Global follicular lymphoma therapeutics market: Increasing government initiatives
Increasing government funding such as Cancer Breakthroughs 2020 are expected to propel the growth of the global follicular lymphoma therapeutics market. Cancer Breakthroughs 2020, previously known as Cancer Moonshot 2020, is an initiative taken by the US government in 2016 for the development of research on the vaccine-based immunotherapies to fight cancer.
According to a senior analyst at Technavio for research on infectious and rare diseases, “In December 2016, the US Congress authorized funding of USD 1.8 billion to the Cancer Breakthroughs 2020 for a period of seven years, with initial funding of USD 300 million in 2017. By inviting the pharmaceutical players to join the initiative, the Cancer Breakthroughs 2020 program plans on making the cancer immunotherapy medicines one of its major areas of focus. The participants of this program include CELGENE, NantWorks, and Amgen.”
Global follicular lymphoma therapeutics market: Segmentation analysis
The global follicular lymphoma therapeutics market research report provides market segmentation by molecule type (biologicals and small molecules) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
The biologicals segment held the largest market share in 2017, contributing to over 56% of the market. This molecule type segment will dominate the global market throughout the forecast period.
The Americas held the largest share of the market in 2017, accounting for close to 44% share, followed by EMEA and APAC respectively. The follicular lymphoma therapeutics market in APAC is expected to witness a faster growth during the forecast period. Factors such as technological advances in the diagnosis of follicular lymphoma and the expected launch of new product offerings due to the existence of strong pipeline are anticipated to drive the market growth during the forecast period.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.